Ranolazine is an antianginal drug that inhibits a number of ion currents that are important for the genesis of transmembrane cardiac action potential. It was initially developed as an antianginal agent but was found to additionally exert antiarrhythmic actions, due to its multichannel-blocking properties. In recent years, several studies about the antiarrhythmic properties of ranolazine were conducted, demonstrating the beneficial effects of this drug in both atrial and ventricular arrhythmias, such as atrial fibrillation, ventricular premature beats, ventricular tachycardia, torsades de pointes, and ventricular fibrillation. Our aim is to briefly review the main points of these studies, most more experimental than clinical
Torsades de pointes (TdP) tachycardias are triggered, polymorphic ventricular arrhythmias arising f...
Introduction: Atrial fibrillation (AF) is a frequent occurrence with advancing age and is associated...
ObjectivesThis study investigated whether ranolazine reduces dofetilide-induced torsades de pointes ...
Ranolazine is an antianginal drug that inhibits a number of ion currents that are important for the ...
BACKGROUND: Ranolazine, a piperazine derivative, reduces ischemia via inhibition of the late phase o...
# The Author(s) 2012. This article is published with open access at Springerlink.com Abstract The la...
Aims: Ranolazine is an antiischemic and antianginal agent, but experimental and preclinical data pro...
International audienceIschemic heart disease is a significant public health problem with high mortal...
The aim of this study was to investigate the effects of a combination of ranolazine with different s...
Ranolazine is a piperazine derivative approved as an antianginal. Primarily used as a second-line an...
Introduction: In vitro studies and ambulatory ECG recordings from the MERLIN TIMI-36 clinical trial ...
Prolongation of the QT interval of the ECG is associated with increased risk of torsades de pointes ...
Introduction: Pharmacological rhythm control of atrial fibrillation (AF) in patients with structural...
Chronic angina represents a major burden for public health systems because of its poor prognosis and...
Chronic angina represents a major burden for public health systems because of its poor prognosis and...
Torsades de pointes (TdP) tachycardias are triggered, polymorphic ventricular arrhythmias arising f...
Introduction: Atrial fibrillation (AF) is a frequent occurrence with advancing age and is associated...
ObjectivesThis study investigated whether ranolazine reduces dofetilide-induced torsades de pointes ...
Ranolazine is an antianginal drug that inhibits a number of ion currents that are important for the ...
BACKGROUND: Ranolazine, a piperazine derivative, reduces ischemia via inhibition of the late phase o...
# The Author(s) 2012. This article is published with open access at Springerlink.com Abstract The la...
Aims: Ranolazine is an antiischemic and antianginal agent, but experimental and preclinical data pro...
International audienceIschemic heart disease is a significant public health problem with high mortal...
The aim of this study was to investigate the effects of a combination of ranolazine with different s...
Ranolazine is a piperazine derivative approved as an antianginal. Primarily used as a second-line an...
Introduction: In vitro studies and ambulatory ECG recordings from the MERLIN TIMI-36 clinical trial ...
Prolongation of the QT interval of the ECG is associated with increased risk of torsades de pointes ...
Introduction: Pharmacological rhythm control of atrial fibrillation (AF) in patients with structural...
Chronic angina represents a major burden for public health systems because of its poor prognosis and...
Chronic angina represents a major burden for public health systems because of its poor prognosis and...
Torsades de pointes (TdP) tachycardias are triggered, polymorphic ventricular arrhythmias arising f...
Introduction: Atrial fibrillation (AF) is a frequent occurrence with advancing age and is associated...
ObjectivesThis study investigated whether ranolazine reduces dofetilide-induced torsades de pointes ...